
Image: Ed Uthman from Houston, TX, USA via Wikimedia Commons (CC BY 2.0)
BioPharma Dive, 5 November 2026
A launch far ahead of forecasts
Revolution Medicines reported $198 million in third-quarter revenue from Rasonque (daraxonrasib), its RAS(ON) inhibitor for metastatic pancreatic cancer, covering only about five weeks on the US market after FDA approval on 26 August 2026. Investors had expected $50–100 million. More than 5,000 US patients were treated by 30 September, prescribed by about 2,700 doctors, around 40% of them in academic centres. One TD Cowen analyst described it as “the best oncology drug launch in history”, and several analysts raised their fourth-quarter forecasts.
The company urged caution. Part of the quarter came from patients moving across from an early access programme that has now closed, and Revolution’s commercial chief said it was too early to judge the normal path of the launch. The fourth quarter should give a clearer baseline.
Why it matters
Rasonque is not a degrader and not a classic small molecule drug. It is a molecular glue; tri-complex inhibitor: the drug first binds the abundant carrier protein cyclophilin A, and that pair then grips active RAS and blocks its signalling. Strong early uptake shows that doctors, payers and patients will embrace a medicine built on a non-degrading molecular glue. We see this as commercial, not just clinical, validation of the carrier-recruiting strategy behind our own FKBP and rapalog approach.
Partners and investors interested in carrier-recruiting molecular glues are welcome to get in touch.